The growing availability of anti-VEGF biosimilars for retinal diseases offers significant potential to expand treatment options, increase patient access, and reduce healthcare costs. However, limited familiarity with regulatory processes, ongoing questions concerning safety and efficacy, and administrative hurdles can reduce adoption of biosimilars by healthcare professionals. Join an expert retina specialist as they review the approval and regulatory requirements for anti-VEGF biosimilars, provide strategies for patient education and access support, and offer practical guidance on integrating effective shared decision-making into treatment planning. You will also gain immediate access to three point-of-care resources to reference in your daily practice.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/biosimilars-clear-view-addressing-barriers-adoption-integration-biosimilars
- Start Date: 2024-10-16 05:00:00
- End Date: 2024-10-16 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.25 hours
AMA PRA Category 1 Credit™️: 0.25 hours
Nursing: 0.25 hours
Pharmacy: 0.25 hours - Commercial Support: Source: Coherus Biosciences - Amount: 30000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all